Company Profile

Lynthera Corporation
Profile last edited on: 8/15/2022      CAGE: 79RQ5      UEI: EHB9K3ECWV79

Business Identifier: Novel therapy to improve treatment of eye disease.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1200 Corporate Boulevard
Lancaster, PA 17601
   (717) 696-8917
Location: Single
Congr. District: 11
County: Lancaster

Public Profile

A technology company structured around research into novel therapy(ies) to improve the treatment of eye disease, Lynthera has developed a Drug Delivery Contact Lens (DDCL) structured around the use of nanotechnology to deliver topical eye drops. Offfering significant advantages over currently available systems, the primary focus at this juncture is development of the approach to treat glaucoma. If determined to be effective, the platform has the potential to create a new paradigm of drug delivery that could transform the broader field of eye care.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 NIH $300,000
Project Title: Drug delivery platform for ocular allergy therapy
2021 1 NIH $300,000
Project Title: Sustained delivery technology for Cyclosporine a in the treatment of autoimmune response

Key People / Management

  Jeff Yang -- Co-Founder, President & Chief Executive Officer

  Roman Domszy -- Senior Research Scientist

  Arthur Yang

Company News

There are no news available.